作者
Katherine Beck, Guy Hindley, Faith Borgan, Cedric Ginestet, Robert McCutcheon, Stefan Brugger, Naomi Driesen, Mohini Ranganathan, Deepak Cyril D’Souza, Matthew Taylor, John H Krystal, Oliver D Howes
发表日期
2020/5/1
来源
JAMA network open
卷号
3
期号
5
页码范围
e204693-e204693
出版商
American Medical Association
简介
Importance
Ketamine hydrochloride is increasingly used to treat depression and other psychiatric disorders but can induce schizophrenia-like or psychotomimetic symptoms. Despite this risk, the consistency and magnitude of symptoms induced by ketamine or what factors are associated with these symptoms remain unknown.
Objective
To conduct a meta-analysis of the psychopathological outcomes associated with ketamine in healthy volunteers and patients with schizophrenia and the experimental factors associated with these outcomes.
Data Sources
MEDLINE, Embase, and PsychINFO databases were searched for within-participant, placebo-controlled studies reporting symptoms using the Brief Psychiatric Rating Scale (BPRS) or the Positive and Negative Syndrome Scale (PANSS) in response to an acute ketamine challenge in healthy participants or patients with schizophrenia.
Study Selection
Of 8464 citations …
学术搜索中的文章
K Beck, G Hindley, F Borgan, C Ginestet… - JAMA network open, 2020